摘要
目的:观察胃尔康片联合瑞巴派特治疗脾胃虚弱型慢性浅表性胃炎(CSG)的临床疗效。方法:按随机数字表法将84例脾胃虚弱型CSG患者分为对照组与治疗组各42例。对照组给予瑞巴派特片治疗,治疗组给予胃尔康片联合瑞巴派特治疗。比较2组治疗前后中医证候积分、视觉模拟评分法(VAS)、日常生活能力量表(ADL)评分及血清前列腺素E_(2)(PGE_(2))、表皮细胞生长因子(EGF)水平,评估2组临床疗效、不良反应发生及疾病复发情况。结果:治疗组总有效率97.62%,高于对照组80.95%(P<0.05)。2组治疗后中医证候积分、VAS评分及EGF水平均较治疗前降低(P<0.05),ADL评分及血清PGE_(2)水平升高(P<0.05);治疗组治疗后ADL评分及血清PGE_(2)水平高于对照组(P<0.05),EGF水平及中医证候积分、VAS评分低于对照组(P<0.05)。治疗组不良反应发生率、疾病复发率分别为2.38%、0,低于对照组16.67%、11.76%(P<0.05)。结论:胃尔康片联合瑞巴派特治疗脾胃虚弱型CSG疗效确切,能改善患者疼痛及生活质量,调节PGE_(2)、EGF水平,降低疾病复发率,安全性较高。
Objective:To observe the clinical effect of the therapy of Wei'erkang Tablets combined with Rebamipide on chronic superficial gastritis (CSG) of spleen-stomach weakness type.Methods:A total of84 CSG patients of spleen-stomach weakness type were divided into the control group and the treatment group according to the random number table method,with 42 cases in each group.The control group was given Rebamipide for treatment,and the treatment group was treated with Wei'erkang Tablets combined with Rebamipide.Before and after treatment,the traditional Chinese medicine (TCM) syndrome scores,scores of Visual Analogue Scale (VAS) and Activities of Daily Living (ADL) scale and levels of serum prostaglandin E_(2)(PGE_(2)) and epidermal growth factor (EGF) were compared between the two groups;the clinical effects,incidence of adverse reactions and recurrence of disease in both groups were evaluated.Results:The total effective rate was 97.62%in the treatment group,higher than that of 80.95%in the control group (P<0.05).After treatment,the TCM syndrome scores,VAS scores and EGF levels in both groups were decreased when compared with those before treatment (P<0.05),the ADL scores and serum PGE_(2) levels increased (P<0.05);ADL scores and serum PGE_(2) levels in the treatment group were higher than those in the control group after treatment (P<0.05),and the EGF levels,TCM syndrome score and VAS score were lower than those in the control group (P<0.05).The incidence of adverse reactions and recurrence of disease were 2.38%and 0 in the treatment group,lower than those of 16.67%and 11.76%in the control group,respectively.Conclusion:The therapy of Wei'erkang Tablets combined with Rebamipide has a definite curative effect on CSG of spleen-stomach weakness type,which can improve the pain and quality of life of patients,regulate the levels of PGE_(2) and EGF,decrease the recurrence of disease with good safety.
作者
徐微
边君
何雪云
徐建光
XU Wei;BIAN Jun;HE Xueyun;XU Jianguang(Department of Digestive Medicine,Quzhou People's Hospital,Quzhou Zhejiang 324000,China)
出处
《新中医》
CAS
2023年第19期83-87,共5页
New Chinese Medicine
